Aspire Biopharma Holdings, Inc. vs Alterity Therapeutics Limited — Valuation Comparison 2026
Access all valuation models for ASBP vs ATHE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →ASBP scores higher with a 4.6/10 quality rating vs ATHE's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Aspire Biopharma Holdings, Inc. (ASBP) and Alterity Therapeutics Limited (ATHE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
ASBP currently trades at $5.53 with a QOC of 4.6/10, while ATHE trades at $4.08 with a QOC of 1.8/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).